Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab

L. C. Olmos, M. S. Sayed, A. L. Moraczewski, Steven J Gedde, Philip J Rosenfeld, W. Shi, William J Feuer, Richard K Lee

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

Aims: To compare the outcomes of neovascular glaucoma (NVG) treated with and without intravitreal bevacizumab in a large case comparison study. Methods: The study is a retrospective, comparative, case series of 163 eyes of 151 patients with NVG, including 99 treated without and 64 treated with intravitreal bevacizumab. Medical and surgical treatments for NVG were assessed. The main outcome measures were visual acuity (VA) and intraocular pressure (IOP). Results: At the time of NVG diagnosis, the median VA was count fingers (CF) in the non-bevacizumab group and 2/300 in the bevacizumab group. IOP (mean±SD) was 43.1±13.0 mm Hg in the non-bevacizumab group and 40.8±11.5 mm Hg in the bevacizumab group. IOP (mean±SD) decreased to 18.3±13.8 mm Hg in the non-bevacizumab group and 15.3±8.0 mm Hg in the bevacizumab group, and the median VA was CF in both treatment groups at a mean follow-up of 12 months. Panretinal photocoagulation (PRP) substantially reduced the need for glaucoma surgery (P

Original languageEnglish (US)
Pages (from-to)463-472
Number of pages10
JournalEye (Basingstoke)
Volume30
Issue number3
DOIs
StatePublished - Mar 1 2016

    Fingerprint

ASJC Scopus subject areas

  • Ophthalmology

Cite this